Table 2. . Ongoing trials of neoadjuvant immunotherapy and targeted therapy in potentially resectable melanoma.

Study/NCT ID	Design	Randomized?	Primary outcome	Treatment used	Main findings/status
NCT02306850	Phase IIB	N/A	Resectability rate at 24 weeks	Pembrolizumab	Recruiting
NCT01608594	Phase II	Yes	Safety	10 mg/kg ipilimumab + HDI-α-2b or 3 mg/kg ipilimumab + HDI-α-2b	Recruiting
NCT02339324	Phase II	N/A	Safety	Pembrolizumab ± HDI-α-2b	Recruiting
NCT02519322	Phase II	Yes	Pathologic response	Neoadjuvant/adjuvant nivolumab vs neoadjuvant ipilimumab and nivolumab and adjuvant nivolumab	Not yet open
Targeted therapy
NCT02303951	Phase II	N/A	Percentage of patients who become resectable at 18 weeks	Vemurafenib and cobimetinib	Recruiting
NCT02036086	Phase II	N/A	Feasibility	Vemurafenib and cobimetinib	Recruiting
NCT01972347	Phase II	N/A	Proportion of viable tissue after 12 weeks of treatment	Dabrafenib + trametinib	Recruiting
NCT02231775	Phase II	Yes	1-year recurrence-free survival	Surgery vs dabrafenib + trametinib followed by surgery	Recruiting
T-VEC
NCT02211131	Phase II	Yes	Recurrence-free survival	Surgery vs T-VEC followed by surgery	Recruiting

HDI: High-dose IFN-α-2b; T-VEC: Talimogene laherparepvec.